Last reviewed · How we verify

Levocetirizine DiHCl

Dr. Reddy's Laboratories Limited · Phase 1 active Small molecule

Levocetirizine DiHCl is a Small molecule drug developed by Dr. Reddy's Laboratories Limited. It is currently in Phase 1 development. Also known as: XYZAL.

At a glance

Generic nameLevocetirizine DiHCl
Also known asXYZAL
SponsorDr. Reddy's Laboratories Limited
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Levocetirizine DiHCl

What is Levocetirizine DiHCl?

Levocetirizine DiHCl is a Small molecule drug developed by Dr. Reddy's Laboratories Limited.

Who makes Levocetirizine DiHCl?

Levocetirizine DiHCl is developed by Dr. Reddy's Laboratories Limited (see full Dr. Reddy's Laboratories Limited pipeline at /company/dr-reddy-s-laboratories-limited).

Is Levocetirizine DiHCl also known as anything else?

Levocetirizine DiHCl is also known as XYZAL.

What development phase is Levocetirizine DiHCl in?

Levocetirizine DiHCl is in Phase 1.

Related